Anticoagulant Properties of Extracellular Slime Substance Produced by Staphylococcus Epidermidis

Summary

Slime produced by S. epidermidis strain KH 11 was extracted with phenol-saline. The saline phase was fractionated on a DEAE-Sepharose CL-6B column. The crude slime solution and its phenol-saline fraction were found to possess anticoagulant properties. They inhibited the coagulation of human plasma by thrombin, prolonged the activated partial thromboplastin time, but did not change the rate of plasma coagulation by reptilase. The anticoagulant effect of slime could be neutralized by rather high concentrations of protamine sulphate. In the presence of plasma, the staphylococcal slime also inhibited in a concentration dependent fashion the amidolytic activity of thrombin and factor Xa against synthetic chromogenic substrates. Both antithrombin III (AT III) and other plasma component(s), presumably heparin cofactor II, were required for the full expression of the slime effect. The anticoagulant action of slime was markedly less AT III dependent than that of heparin. The activity was resistant to heating (100° C, 30 min). Slime and its fractions were stronger inhibitors of thrombin than of factor Xa. Fraction IV separated by DEAE-Sepharose chromatography and particularly rich in galactose and glucuronic acid had the highest inhibitory potency. It is conceivable that slime component(s) similar to glycosaminogly-cans from other sources can carry the anticoagulant activity.

Keywords

Staphylococcal slime - Antithrombin activity - Anti-Xa activity

• References

• 1 Duma RJ, Warner JF, Dalton HP. Septicemia from intravenous infusions. N Engl J Med 1977; 284: 257-260
• 2 Bender JW, Hughes WT. Fatal Staphylococcus epidermidis sepsis following bone marrow transplantation. John Hopkins Med J 1980; 146: 13-15
• 3 Masur H, Johnson WD. Prosthetic valve endocarditis. J Thorac Cardiovasc Surg 1980; 80: 31-37
• 4 Steinchfield FE, Bigliani LU, Neu HC, Gross TP, Foster CR. Late hematogenous infection of total joint replacement. J Bone Joint Surg 1980; 62A: 1345-1350
• 5 Choo MH, Holmes DR, Gersh BJ, Maloney JD, Merideth J, Pluth JR, Trusty J. Permanent pacemaker infections: Characterization and management. Am J Cardiol 1981; 48: 559-564
• 6 Rubin J, Rogers WA, Taylor HM, Everett ED, Prowant BF, Fruto LV, Nolf KD. Peritonitis during continuous ambulatory peritoneal dialysis. Ann Intern Med 1980; 92: 7-13
• 7 Christensen GD, Simpson WA, Bisno AL, Beachey EH. Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immunol 1982; 37: 318-326
• 8 Peters G, Locci R, Pulverer G. Microbial colonization of prosthetic devices. II. Scanning electron microscopy of naturally infected intravenous catheters. Zentralbl Bakteriol (Orig B) Hyg 1981; 173: 293-299
• 9 Peters G, Locci R, Pulverer G. Adherence and growth of coagulase-negative staphylococci on surfaces of intravenous catheters. J Infect Dis 1982; 146: 479-482
• 10 Gray ED, Verstegen M, Peters G, Regelmann WE. Effect of extracellular slime substance from Staphylococcus epidermidis on the human cellular immune response. Lancet 1984; 1: 365-367
• 11 Ludwicka A, Uhlenbruck G, Peters G, Seng PN, Gray ED, Jeliaszewicz J, Pulverer G. Investigation on extracellular slime substance produced by Staphylococcus epidermidis. Zentralbl Bakteriol (Orig A) 1984; 258: 256-267
• 12 Uhlenbruck G. Über die von den Genen MM und MN gebildete Blutgruppensubstanz. J Immun Forsch 1961; 121: 420-424
• 13 Miller-Andersson M, Borg H, Andersson LO. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-452
• 14 Poller L, Thomson JM. The partial thromboplastin time test. J Clin Pathol 1972; 25: 1038-1044
• 15 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
• 16 Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8: 859-867
• 17 Hubbard AR, Jennings CA, Barrowcliffe TW. Anticoagulant properties in vitro of heparan sulphates. Thromb Res 1984; 35: 567-576
• 18 Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blajchman MA. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 742-747
• 19 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
• 20 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
• 21 Tollefsenz DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
• 22 Abildgaard U, Larsen ML. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb Res 1984; 35: 257-266
• 23 Scully MF, Kakkar VV. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54). Thromb Res 1984; 36: 187-194
• 24 Wilkinson BJ. Staphylococcal capsules and slime. Staphylococci and Staphylococcal Infect 1983; 2: 481-523